A Phase 1/2 Study of Selinexor in Combination with Standard of Care (SoC) Therapy for Newly Diagnosed or RecurrentGlioblastoma

Contact:

NCT Number:

Protocol:

AAAT0359

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

Specialty Area(s)

Principal Investigator

Profile Headshot
  • Chief, Division of Neuro-Oncology
  • Co-Director, Brain Tumor Center
  • Associate Director for Clinical Trials, Herbert Irving Comprehensive Cancer Center
  • Associate Dean of Clinical Trials at VP&S